Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bangkok Genomics Innovation PCL's EBIT per Share for the
three
months ended in Dec. 2025 was ฿0.05.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was ฿0.08.
During the past 12 months, the average EBIT per Share Growth Rate of Bangkok Genomics Innovation PCL was -9.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -14.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 10.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Bangkok Genomics Innovation PCL's EBIT per Share or its related term are showing as below:
BKK:BKGI'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -19.7 Med: -14.5 Max: 32.6
Current: -14.5
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Bangkok Genomics Innovation PCL was 32.60% per year. The lowest was -19.70% per year. And the median was -14.50% per year.
BKK:BKGI's 3-Year EBIT Growth Rate is ranked worse than 79.39% of 165
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.2
vs BKK:BKGI: -14.50
Bangkok Genomics Innovation PCL (BKK:BKGI) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Bangkok Genomics Innovation PCL EBIT per Share Related Terms
Bangkok Genomics Innovation PCL EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Genomics Innovation PCL EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Genomics Innovation PCL (BKK:BKGI) has a EBIT per Share of ฿0.08 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bangkok Genomics Innovation PCL and its competitors. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #131 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 79.4%.
Is Bangkok Genomics Innovation PCL's EBIT per Share too high?
Bangkok Genomics Innovation PCL's current EBIT per Share is ฿0.08. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #131 out of 165 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #131 out of 165 companies for EBIT per Share. This places Bangkok Genomics Innovation PCL in the lower half of its industry. The industry median EBIT per Share is 13.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.20, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bangkok Genomics Innovation PCL and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Genomics Innovation PCL's current EBIT per Share is ฿0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current EBIT per Share of ฿0.08. The current EBIT per Share is ฿0.08. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current EBIT per Share is ฿0.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL Business Description
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score
Get the complete analysis for BKK:BKGI
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
